X hits on this document





11 / 11



1. Schiffman MH, Hildesheim A. Cervical cancer. In: Schottenfeld D, Fraumeni JFF Jr, eds. Cancer Epide- miology and Prevention. Oxford, England: Oxford Uni- versity Press; 2006:1044-1067. 2. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 viruslike particle vaccine in young wom- en: a randomized double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005; 6(5):271-278. 3. Harper DM, Franco EL, Wheeler CM, et al. Sus- tained efficacy up to 4.5 years of a bivalent L1 virus- like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet. 2006;367(9518):1247-1255. 4. Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007; 356(19):1928-1943. 5. Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915-1927. 6. Mao C, Koutsky LA, Ault KA, et al. Efficacy of hu- man papillomavirus-16 vaccine to prevent cervical in- traepithelial neoplasia: a randomized controlled trial. Obstet Gynecol. 2006;107(1):18-27. 7. Stanley M, Lowy DR, Frazer I. Prophylactic HPV vaccines: underlying mechanisms. Vaccine. 2006; 24(suppl 3):S106-S113. 8. Lowy DR, Schiller JT. Prophylactic human papillo- mavirus vaccines. J Clin Invest. 2006;116(5):1167- 1173. 9. Nardelli-Haefliger D, Wirthnew D, Schiller JT, et al. Specific antibody levels at the cervix are menstrual- cycle dependent in women vaccinated with human papillomavirus type 16 virus like particles. J Natl Can- cer Inst. 2003;95(15):1128-1137. 10. Giannini SL, Hanon E, Moris P, et al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/

aluminium salt combination (AS04) compared to aluminium salt only. Vaccine. 2006;24(33-34):5937- 5949. 11. Villa LL, Ault KA, Giuliano AR, et al. Immuno- logic responses following administration of a vaccine targeting human papillomavirus types 6, 11, 16, and

  • 18.

    Vaccine. 2006;24(27-28):5571-5583.

  • 12.

    Pinto LA, Edwards J, Castle PE, et al. Cellular im-

mune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombi- nant HPV-16 L1 viruslike particles. J Infect Dis. 2003; 188(2):327-338. 13. Pinto LA, Castle PE, Roden RB, et al. HPV-16 L1 VLP vaccine elicits a broad-spectrum of cytokine re- sponses in whole blood. Vaccine. 2005;23(27):3555- 3564. 14. Emeny RT, Wheeler CM, Jansen KU, et al. Prim- ing of human papillomavirus type 11-specific hu- moral and cellular immune responses in college-aged women with a viruslike particle vaccine. J Virol. 2002; 76(15):7832-7842. 15. Peng S, Frazer IH, Fernando GJ, Zhou J. Papillo- mavirus viruslike particles can deliver defined CTL epi- topes to the MHC class I pathway. Virology. 1998;240

  • (1)


  • 16.

    Kirnbauer R, Chandrachud LM, O’Neil BW, et al.

Viruslike particles of bovine papillomavirus type 4 in prophylactic and therapeutic immunization. Virology. 1996;219(1):37-44. 17. Schiffman M, Herrero R, Desalle R, et al. The car- cinogenicity of human papillomavirus types reflects vi- ral evolution. Virology. 2005;337(1):76-84. 18. Wright TC Jr, Schiffman M, Solomon D, et al. In- terim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol. 2004;103(2):304- 309. 19. Saslow D, Runowicz CD, Solomon D, et al. Ameri- can Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA Cancer J Clin. 2002;52(6):342-362. 20. Atypical Squamous Cells of Undetermined Sig-

nificance/Low-Grade Squamous Intraepithelial Le- sions Triage Study Group. Human papillomavirus test- ing for triage of women with cytologic evidence of low- grade squamous intraepithelial lesions: baseline data from a randomized trial. J Natl Cancer Inst. 2000; 92(5):397-402. 21. Kleter B, van Doorn LJ, Schrauwen L, et al. De- velopment and clinical evaluation of a highly sensi- tive PCR-reverse hybridization line probe assay for de- tection and identification of anogenital human papillomavirus. J Clin Microbiol. 1999;37(8): 2508-2517. 22. Kleter B, van Doorn LJ, ter Schegget J, et al. Novel short-fragment PCR assay for highly sensitive broad- spectrum detection of anogenital human papillomaviruses. Am J Pathol. 1998;153(6): 1731-1739. 23. van Doorn LJ, Molijn A, Kleter B, Quint W, Co- lau B. Highly effective detection of human papilloma- virus 16 and 18 DNA by a testing algorithm combin- ing broad-spectrum and type-specific PCR. J Clin Microbiol. 2006;44(9):3292-3298. 24. Baay MF, Quint WG, Koudstaal J, et al. Compre- hensive study of several general and type-specific primer pairs for detection of human papillomavirus DNA by PCR in paraffin-embedded cervical carcinomas. J Clin Microbiol. 1996;34(3):745-747. 25. Schachter J, Hook EW III, McCormack WM, et al. Ability of the Digene Hybrid Capture II test to iden- tify Chlamydia trachomatis and Neisseria gonor- rhoeae in cervical specimens. J Clin Microbiol. 1999; 37(11):3668-3671. 26. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. Biometrika. 1986;73:13-22. 27. Schiffman M, Castle PE. The promise of global cervical-cancer prevention. N Engl J Med. 2005;353(20):2101-2104. 28. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 viruslike particle vaccine in preven- tion of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet. 2004;364(9447):1757-1765.

©2007 American Medical Association. All rights reserved.

(Reprinted) JAMA, August 15, 2007—Vol 298, No. 7


Document info
Document views40
Page views40
Page last viewedSun Jan 22 14:55:50 UTC 2017